Certara (NASDAQ:CERT) Issues FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.420-0.460 for the period, compared to the consensus EPS estimate of 0.450. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $420.0 million.

Certara Price Performance

Certara stock opened at $13.53 on Thursday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $2.18 billion, a P/E ratio of -67.65, a PEG ratio of 9.29 and a beta of 1.64. The business has a 50-day moving average of $11.62 and a 200-day moving average of $11.43. Certara has a 1 year low of $8.64 and a 1 year high of $17.94.

Analysts Set New Price Targets

Several brokerages have commented on CERT. Stephens reaffirmed an “overweight” rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective on the stock. Robert W. Baird boosted their target price on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. KeyCorp increased their price target on Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Barclays cut their price objective on Certara from $13.00 to $11.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Certara has a consensus rating of “Moderate Buy” and an average target price of $15.17.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.